Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

Phase 1

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Leukemia
Lymphoma
Myelodysplastic Syndromes

Interventions: Biological: anti-thymocyte globulin
Biological: sargramostim
Drug: busulfan
Drug: fludarabine phosphate
Drug: mycophenolate mofetil
Drug: tacrolimus
Procedure: umbilical cord blood transplantation

First Posted Date: 2006-03-13

Last Posted Date: 2017-10-12

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 7

Registration Number: NCT00301951

Locations: 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States

Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders

Phase 2

Completed

Conditions: Congenital Amegakaryocytic Thrombocytopenia
Severe Congenital Neutropenia
Diamond-blackfan Anemia
Leukemia
Myelodysplastic Syndromes

Interventions: Biological: alemtuzumab
Drug: busulfan
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: methotrexate
Drug: methylprednisolone
Procedure: allogeneic bone marrow transplantation
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Procedure: umbilical cord blood transplantation

First Posted Date: 2006-03-13

Last Posted Date: 2017-09-28

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 35

Registration Number: NCT00301834

Locations: 🇺🇸
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States
🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease

Phase 1

Completed

Conditions: Congenital Amegakaryocytic Thrombocytopenia
Leukemia
Myelodysplastic Syndromes
Severe Congenital Neutropenia

Interventions: Biological: anti-thymocyte globulin
Biological: therapeutic allogeneic lymphocytes
Drug: fludarabine phosphate
Drug: thiotepa
Procedure: allogeneic bone marrow transplantation
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: in vitro-treated peripheral blood stem cell transplantation
Radiation: total-body irradiation

First Posted Date: 2006-02-24

Last Posted Date: 2012-11-12

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 21

Registration Number: NCT00295971

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer

Not Applicable

Completed

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

Interventions: Biological: anti-thymocyte globulin
Biological: filgrastim
Biological: therapeutic allogeneic lymphocytes
Drug: busulfan
Drug: fludarabine phosphate
Drug: methotrexate
Drug: tacrolimus
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2006-02-24

Last Posted Date: 2012-10-04

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 25

Registration Number: NCT00296023

Locations: 🇺🇸
Alta Bates Comprehensive Cancer Center, Berkeley, California, United States
🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Not Applicable

Conditions: Chronic Myeloproliferative Disorders
Kidney Cancer
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

First Posted Date: 2006-02-24

Last Posted Date: 2014-01-06

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 35

Registration Number: NCT00295997

Locations: 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Fludarabine
Drug: Mitoxantrone
Drug: Rituximab
Drug: Zevalin
Drug: Dexamethasone

First Posted Date: 2006-02-13

Last Posted Date: 2022-04-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 49

Registration Number: NCT00290511

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer

Not Applicable

Completed

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Myelodysplastic Syndromes
Lymphoma

First Posted Date: 2006-02-13

Last Posted Date: 2017-11-29

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 68

Registration Number: NCT00290641

Locations: 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States

Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism

Phase 1

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Biological: Hematopoietic Stem Cell Transplantation
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Campath 1H
Drug: GCSF
Drug: Cyclosporins
Drug: Mycophenolate Mofetil

First Posted Date: 2006-01-26

Last Posted Date: 2018-07-30

Lead Sponsor: Northwestern University

Target Recruit Count: 4

Registration Number: NCT00282412

Locations: 🇺🇸
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States

Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation

Phase 2

Completed

Conditions: Graft Versus Host Disease
GVHD

First Posted Date: 2006-01-26

Last Posted Date: 2014-05-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 31

Registration Number: NCT00282282

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia

Phase 3

Completed

Conditions: Leukemia

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate

First Posted Date: 2006-01-25

Last Posted Date: 2013-09-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 817

Registration Number: NCT00281918

Locations: 🇩🇪
Praxis Fur Hamatologie und Onkologie Ahaus, Ahaus, Germany
🇩🇪
Hamatologische/Onkologische Gemeinschaftspraxis - Augsburg, Augsburg, Germany
🇩🇪
Onkologische Schwerpunktpraxis Bielefeld, Bielefeld, Germany

and more 157 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy